BF Biosciences Past Earnings Performance
Past criteria checks 4/6
BF Biosciences has been growing earnings at an average annual rate of 24.3%, while the Pharmaceuticals industry saw earnings growing at 3% annually. Revenues have been growing at an average rate of 33.8% per year. BF Biosciences's return on equity is 16.2%, and it has net margins of 10.5%.
Key information
24.3%
Earnings growth rate
24.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 20.2% |
| Revenue growth rate | 33.8% |
| Return on equity | 16.2% |
| Net Margin | 10.5% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How BF Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 3,540 | 371 | 669 | 0 |
| 30 Jun 23 | 1,810 | 149 | 161 | 0 |
| 30 Jun 22 | 1,521 | 307 | 187 | 0 |
| 30 Jun 21 | 1,755 | 608 | 153 | 0 |
| 30 Jun 20 | 628 | 47 | 61 | 0 |
| 30 Jun 19 | 448 | -44 | 62 | 0 |
Quality Earnings: BFBIO has high quality earnings.
Growing Profit Margin: BFBIO's current net profit margins (10.5%) are lower than last year (10.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BFBIO's earnings have grown significantly by 24.3% per year over the past 5 years.
Accelerating Growth: BFBIO's earnings growth over the past year (97.1%) exceeds its 5-year average (24.3% per year).
Earnings vs Industry: BFBIO earnings growth over the past year (97.1%) exceeded the Pharmaceuticals industry 66.2%.
Return on Equity
High ROE: BFBIO's Return on Equity (16.2%) is considered low.